Claims for Patent: 8,586,045
✉ Email this page to a colleague
Summary for Patent: 8,586,045
Title: | Methods of using anti-CGRP antagonist antibodies |
Abstract: | The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described. |
Inventor(s): | Zeller; Joerg (Ann Arbor, MI), Poulsen; Kristian T. (San Francisco, CA), Abdiche; Yasmina Noubia (Mountain View, CA), Pons; Jaume (San Bruno, CA), Collier; Sierra Lee Jones (Menlo Park, CA), Rosenthal; Arnon (Woodside, CA) |
Assignee: | Labrys Biologics, Inc. (San Mateo, CA) |
Application Number: | 13/179,846 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,586,045 |
Patent Claims: | 1. A method for reducing incidence of or treating at least one vasomotor symptom in an individual, comprising administering to the individual an effective amount of an anti-CGRP
antagonist antibody, wherein said anti-CGRP antagonist antibody is a human monoclonal antibody or a humanized monoclonal antibody.
2. The method according to claim 1, wherein the anti-CGRP antagonist antibody is: (a) an antibody having a CDR H1 as set forth in SEQ ID NO: 3; a CDR H2 as set forth in SEQ ID NO: 4; a CDR H3 as set forth in SEQ ID NO: 5; a CDR L1 as set forth in SEQ ID NO: 6; a CDR L2 as set forth in SEQ ID NO: 7; and a CDR L3 as set forth in SEQ ID NO: 8; or (b) a variant of an antibody according to (a) as shown in Table 6. 3. The method according to claim 1, where said vasomotor symptom is selected from the group consisting of hot flush, a migraine with or without aura, hemiplegic migraine, cluster headache, migrainous neuralgia, chronic headache, and tension headache. 4. The method according to claim 1, wherein the anti-CGRP antagonist antibody has a binding affinity (K.sub.D) to human .alpha.-CGRP of 50 nM or less as measured by surface plasmon resonance at 37.degree. C. 5. The method according to claim 1, wherein the anti-CGRP antagonist antibody comprises a V.sub.H domain comprising SEQ ID NO: 1 and a V.sub.L domain comprising SEQ ID NO: 2. 6. The method according to claim 1, wherein the anti-CGRP antagonist antibody comprises a light chain produced by the expression vector with ATCC Accession No. PTA-6866. 7. The method according to claim 1, wherein the anti-CGRP antagonist antibody comprises a heavy chain produced by the expression vector with ATCC Accession No. PTA-6867. 8. The method according to claim 1, wherein the individual is human. 9. The method of claim 1, wherein said vasomotor symptom is a migraine. 10. The method of claim 1, wherein said anti-CGRP antagonist antibody binds the C-terminal fragment having amino acids 25-37 of CGRP or a C-terminal epitope within amino acids 25-37 of CGRP. 11. The method of claim 1, wherein said anti-CGRP antagonist antibody comprises an Fc region with an impaired effector function. 12. The method of claim 1, wherein route of administration of said anti-CGRP antagonist antibody is selected from the group consisting of systemically, intravenously, subcutaneously, intramuscularly, and transdermally. 13. The method of claim 1, wherein said anti-CGRP antagonist antibody comprises a heavy chain constant region derived from a human IgG2 constant region. 14. The method of claim 1, wherein said anti-CGRP antagonist antibody is formulated with a pharmaceutically acceptable carrier, excipient, and/or stabilizer. 15. The method of claim 1, wherein said anti-CGRP antagonist antibody is a humanized monoclonal antibody. 16. The method of claim 1, wherein the dose of said anti-CGRP antagonist antibody is at least about 3 .mu.g/kg. 17. A method for reducing incidence of or treating headache in a human, comprising administering to the human an effective amount of an anti-CGRP antagonist antibody, wherein said anti-CGRP antagonist antibody is a human monoclonal antibody or a humanized monoclonal antibody. 18. The method according to claim 17, wherein the anti-CGRP antagonist antibody is: (a) an antibody having a CDR H1 as set forth in SEQ ID NO: 3; a CDR H2 as set forth in SEQ ID NO: 4; a CDR H3 as set forth in SEQ ID NO: 5; a CDR L1 as set forth in SEQ ID NO: 6; a CDR L2 as set forth in SEQ ID NO: 7; and a CDR L3 as set forth in SEQ ID NO: 8; or (b) a variant of an antibody according to (a) as shown in Table 6. 19. The method according to claim 17, where said headache is a migraine with or without aura, hemiplegic migraine, cluster headache, migrainous neuralgia, chronic headache, or tension headache. 20. The method according to claim 17, wherein the anti-CGRP antagonist antibody has a binding affinity (K.sub.D) to human .alpha.-CGRP of 50 nM or less as measured by surface plasmon resonance at 37.degree. C. 21. The method according to claim 17, wherein the anti-CGRP antagonist antibody comprises a V.sub.H domain comprising SEQ ID NO: 1 and a V.sub.L domain comprising SEQ ID NO: 2. 22. The method according to claim 17, wherein the anti-CGRP antagonist antibody comprises a light chain produced by the expression vector with ATCC Accession No. PTA-6866. 23. The method according to claim 17, wherein the anti-CGRP antagonist antibody comprises a heavy chain produced by the expression vector with ATCC Accession No. PTA-6867. 24. The method of claim 17, wherein said headache is a migraine. 25. The method of claim 17, wherein said anti-CGRP antagonist antibody binds the C-terminal fragment having amino acids 25-37 of CGRP or a C-terminal epitope within amino acids 25-37 of CGRP. 26. The method of claim 17, wherein said anti-CGRP antagonist antibody comprises an Fc region with an impaired effector function. 27. The method of claim 17, wherein route of administration of said anti-CGRP antagonist antibody is selected from the group consisting of systemically, intravenously, subcutaneously, intramuscularly, and transdermally. 28. The method of claim 17, wherein said anti-CGRP antagonist antibody comprises a heavy chain constant region derived from a human IgG2 constant region. 29. The method of claim 17, wherein said anti-CGRP antagonist antibody is formulated with a pharmaceutically acceptable carrier, excipient, and/or stabilizer. 30. The method of claim 17, wherein said anti-CGRP antagonist antibody is a humanized monoclonal antibody. 31. The method of claim 17, wherein the dose of said anti-CGRP antagonist antibody is at least about 3 .mu.g/kg. |
Details for Patent 8,586,045
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Teva Branded Pharmaceutical Products R&d, Inc. | AJOVY | fremanezumab-vfrm | Injection | 761089 | September 14, 2018 | ⤷ Sign Up | 2025-11-14 |
Teva Branded Pharmaceutical Products R&d, Inc. | AJOVY | fremanezumab-vfrm | Injection | 761089 | January 27, 2020 | ⤷ Sign Up | 2025-11-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,586,045
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 200803484 | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2007054809 | ⤷ Sign Up |
United States of America | 9890211 | ⤷ Sign Up |
United States of America | 9890210 | ⤷ Sign Up |
United States of America | 9884908 | ⤷ Sign Up |
United States of America | 9884907 | ⤷ Sign Up |
United States of America | 9365648 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.